Moreover, with regard to clinical utility, these data support the conclusion that the anti-CTGF monoclonal antibody, FG-3019, may be useful in controlling the progression of renal, pulmonary and hepatic fibrosis in patients with diseases such as diabetic nephropathy, systemi sclerosis or idiopathic pulmonary fibrosis. Here, CCN2 is linked to diabetic kidney disease.